Biomarkers for childhood relapsed acute lymphoblastic leukaemia
Biomarkers for childhood relapsed acute lymphoblastic leukaemia
Are CML patients being treated to the correct standard?
PDL1 expression in thymic tumours
Exciting update on the Repurposing Drugs in Oncology (ReDO) project
Overview of innovation in Hodgkin's lymphoma
Minimal residual disease in multiple myeloma
EHA 2015: Expert opinions on new treatment standard in multiple myeloma
Exploring "bad luck" - why do some patients develop myeloid leukaemia?
New definition for multiple myeloma improves patient outcomes
Treatment and survival of patients with chronic myeloid leukaemia in Europe
Medically under-represented populations: Refining the calculation of accrual targets
ASCO 2015: Latest developments in multiple myeloma